Paclitaxel

Paclitaxel (catalog numbers P106868 analytical standard ≥99%， P106869 ≥99% and P408076 10mM in DMSO ) was first identified in 1971 as a potent anticancer compound. Originally isolated from the bark of the Pacific yew tree (Taxus brevifolia Nutt.), it has since been produced through synthetic and semi-synthetic approaches, ensuring broader accessibility for clinical and research use.

Unlike many traditional antimitotic agents—including Colchicine (C106738 C106740 C106739 C294476 C425287), Vinblastine Sulfate (V100993 V100992 V421608), and Podophyllotoxin (P105537 P105536)—which act by preventing microtubule assembly, paclitaxel functions in a distinct manner. 

It binds directly to β-tubulin and stabilizes preformed microtubules, preventing their depolymerization. This stabilization disrupts the normal dynamics of the mitotic spindle, halting cell division and ultimately inducing programmed cell death (apoptosis).

Therapeutic Applications：Paclitaxel demonstrates strong chemotherapeutic efficacy against a wide range of malignancies. It has been successfully applied in the treatment of leukemias, sarcomas, and solid tumors such as lung cancers. Clinically, it is a well-established therapeutic option for ovarian cancer, breast cancer, lung cancer, head and neck cancers, and Kaposi’s sarcoma.

Aladdin offers both naturally derived and synthetic paclitaxel, along with an array of related taxanes and intermediates for research purposes. Representative products include:

· B114048 B140555 B422969– Baccatin III

· D276061 D425946 – 10-Deacetyltaxol

· E275717 E420474 – 7-Epi-Taxol

· P353638 – Taxol C

· X126271 – Xylosyltaxol

· D107319 D107320 D407943 – Docetaxel

…and many additional derivatives

References

1. Wani MC, Taylor HL, Wall ME, et al. J Am Chem Soc. 1971;93(9):2325–2327.

2. Olmsted JB, Borisy GG. Biochemistry. 1973;12(21):4282–4289.

3. Gensler WJ, Murthy CD, Trammell MH. J Med Chem. 1977;20(5):635–644.

4. Snyder JA, McIntosh JR. Annu Rev Biochem. 1976;45:699–720.

5. Terwogt JM, Nuijen B, Huinink WW, et al. Cancer Treat Rev. 1997;23(2):87–95.

6. Goldspiel BR. Pharmacotherapy. 1997;17(5 Pt 2):110S–125S.

7. Aisner J, Cortes-Funes H. Semin Oncol. 1997;24(1 Suppl 2):S2-113–S2-115.

8. Gehl J, Boesgaard M, Paaske T, et al. Semin Oncol. 1996;23(6 Suppl 15):35–38.

Aladdin: https://www.aladdinsci.com/